6-Methyltryptamine

6-Methyltryptamine (6-Me-T or 6-methyl-T; developmental code name PAL-522) is a serotonin receptor modulator and monoamine releasing agent of the tryptamine family. It is the 6-methyl derivative of tryptamine.

The drug acts as a potent full agonist of the serotonin 5-HT2A receptor, with an EC50Tooltip half-maximal effective concentration of 75.3 nM and an EmaxTooltip maximal efficacy of 110%. It is about 10-fold less potent as a serotonin 5-HT2A receptor agonist than tryptamine itself. In addition to its serotonin 5-HT2A receptor agonism, 6-methyltryptamine is a serotonin–dopamine releasing agent (SDRA), with EC50 values for induction of monoamine release of 51.6 nM for serotonin, 353 nM for dopamine, and >10,000 nM for norepinephrine in rat brain synaptosomes. It shows extremely weak affinity for the dizocilpine (MK-801) site of the NMDA receptor (IC50Tooltip half-maximal inhibitory concentration = 175,000–260,000 nM).

Tryptamines without substitutions at the amine or alpha carbon, such as tryptamine, serotonin (5-hydroxytryptamine; 5-HT), and 5-methoxytryptamine (5-MeO-T), are known to be very rapidly metabolized and thereby inactivated by monoamine oxidase A (MAO-A) in vivo and to have very short elimination half-lives. However, given intravenously at sufficiently high doses, tryptamine is still known to be able to produce weak and short-lived psychoactive effects in humans.

The chemical synthesis of 6-methyltryptamine has been described.

6-Methyltryptamine was first described in the scientific literature by 1965. Its pharmacology was subsequently assessed in greater detail in 2014.

• Substituted tryptamine

• 6-Methyl-DMT

• 6-Methyl-5-MeO-DMT

• 6-Methoxytryptamine

• 6-Hydroxytryptamine

• 6-Fluorotryptamine

• 6-Bromotryptamine

• 6-Methyl-T - Isomer Design